Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical ENS-002 for Atopic Dermatitis
NCT06469385Phase 1Terminated
- Sponsor
- Concerto Biosciences
- Start
- Sep 2024
- Primary completion
- Aug 2025
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label trial of ENS-002 in atopic dermatitis (AD) (3 cohorts), sponsored by Concerto Biosciences. Primary endpoints: Safety of ENS-002 total doses up to 43 days, Safety of ENS-002 dose frequency up to 43 days and 3 more. Started Sep 2024; status: terminated.
02
Drugs
ENS-002
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06469385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06469385.